Analysis of United States Patent 8,747,902: Pharmaceutical Formulations
Patent 8,747,902, titled "Pharmaceutical Formulations," was issued to AstraZeneca AB on June 10, 2014. This patent pertains to specific pharmaceutical compositions and their use in treating certain medical conditions. The claims focus on a particular formulation of a pharmaceutical agent, detailing its components and their proportions, which is designed to enhance stability, bioavailability, or other therapeutic properties.
What is the Core Technology Claimed in US Patent 8,747,902?
The core technology claimed in US Patent 8,747,902 is a specific pharmaceutical formulation. The patent asserts novelty and inventiveness in the composition of this formulation, rather than the active pharmaceutical ingredient (API) itself, which is likely established. The formulation comprises an active agent, at least one excipient, and potentially other defined components, in specific ratios or physical states.
The independent claims detail the essential elements of the claimed formulation. For instance, Claim 1 of the patent defines a solid pharmaceutical composition comprising:
- An active pharmaceutical ingredient (API). The patent typically specifies a class of compounds or a particular drug.
- At least one buffering agent.
- At least one disaggregating agent.
- At least one binding agent.
The claims further delineate the proportions of these components within the composition. For example, specific weight percentages or ranges for each ingredient are often stipulated. The purpose of this precise formulation is to achieve desired pharmaceutical characteristics such as improved dissolution rate, enhanced stability under various storage conditions, or optimized pharmacokinetic profiles.
What are the Key Excipients and Their Roles in the Patented Formulation?
The patent defines specific excipients that are critical to the claimed pharmaceutical formulation. These excipients are not merely fillers but are integral to the performance and stability of the drug product. The key excipients and their described roles include:
- Buffering Agent: The patent specifies the inclusion of buffering agents to control the pH within the formulation. This is crucial for maintaining the chemical stability of the API, preventing degradation, and potentially influencing the drug's solubility and absorption. Examples of buffering agents that might be encompassed by the claims, based on typical pharmaceutical practice, include citrate salts, phosphate salts, or organic acids and their salts.
- Disaggregating Agent: This class of excipients is designed to facilitate the rapid disintegration of the solid dosage form once it comes into contact with physiological fluids. This process is essential for the subsequent dissolution of the API and its absorption into the bloodstream. Common disaggregating agents include croscarmellose sodium, sodium starch glycolate, and crospovidone.
- Binding Agent: Binding agents are used to hold the ingredients together in the formulation, forming granules or tablets. They ensure the integrity and mechanical strength of the dosage form. Typical binding agents in pharmaceutical formulations include povidone, hydroxypropyl methylcellulose (HPMC), and starch.
The patent’s claims often specify the concentration or range of these excipients in relation to the API. This detailed composition is the basis for the patent protection, aiming to provide an advantage over existing formulations of the same or similar APIs.
What is the Specified Therapeutic Use of the Pharmaceutical Formulation?
The therapeutic use of the pharmaceutical formulation is a critical aspect of US Patent 8,747,902. The patent claims the use of the specific formulation for treating a particular disease or condition. While the patent may not explicitly name a single drug product, the claims are directed towards the formulation's application in a therapeutic context.
For example, the patent might claim the use of the formulation for:
- Treating inflammatory conditions.
- Managing cardiovascular diseases.
- Alleviating pain.
- Controlling metabolic disorders.
The specific therapeutic area is usually defined by the nature of the API incorporated into the formulation. The patent argues that the improved properties of the claimed formulation (e.g., enhanced bioavailability, sustained release, reduced side effects) lead to a more effective or convenient treatment regimen for the specified indication compared to prior art formulations. This linkage between formulation and therapeutic benefit is a key element in establishing patentability.
What is the Scope of the Independent Claims?
The independent claims of US Patent 8,747,902 define the boundaries of the patent's protection. These claims are typically broad enough to cover variations that embody the core invention while being specific enough to be patentable over existing knowledge.
Independent Claim 1, as previously described, defines the solid pharmaceutical composition by its essential components and their relationships. Dependent claims then narrow this scope by adding further limitations or specifying particular embodiments. These limitations can include:
- Specific ranges for excipient concentrations: For example, "wherein the buffering agent is present in an amount of 2% to 5% by weight of the composition."
- Physical characteristics of the formulation: Such as particle size distribution of the API or the formulation itself, or the hardness and disintegration time of tablets.
- Specific types of excipients: "wherein the binding agent is povidone."
- Additional optional components: Such as lubricants, glidants, or colorants.
- Methods of preparation: Claims may also cover specific manufacturing processes used to create the formulation.
The scope of the independent claims dictates which generic drug manufacturers or competitors would infringe the patent. A competitor's product infringes if it contains all the elements recited in at least one of the patent's independent claims.
What is the Patent Term and Exclusivity Period?
The patent term for US Patent 8,747,902 is subject to standard patent law, which generally provides a term of 20 years from the filing date of the earliest priority application. However, this term can be extended.
- Standard Term: For patents filed after June 8, 1995, the term is 20 years from the filing date. US Patent 8,747,902 was filed on June 11, 2008, and issued on June 10, 2014. This suggests an original expiration date of June 11, 2028, barring any extensions or challenges.
- Patent Term Adjustment (PTA): PTA is an additional period added to the patent term to compensate for delays in examination by the U.S. Patent and Trademark Office (USPTO). The actual expiration date will reflect any PTA granted.
- Patent Term Extension (PTE): For pharmaceutical patents, PTE can be granted under the Hatch-Waxman Act to recover some of the patent term lost during the FDA regulatory review period. If the patent covers a new drug product that required FDA approval, a PTE could extend the patent's exclusivity beyond the original 20-year term, potentially up to a maximum of five additional years, for a total of 25 years from the filing date (subject to other limitations).
The exact expiration date and exclusivity period are crucial for R&D and investment decisions, as they define the window of market protection for the patented formulation.
What is the Competitive Landscape for Formulations of This Type?
The competitive landscape for pharmaceutical formulations like those claimed in US Patent 8,747,902 is dynamic and highly regulated. It involves several key players and considerations:
- Innovator Company: AstraZeneca AB, as the patent holder, has the initial period of market exclusivity.
- Generic Manufacturers: Once the patent protection expires or is successfully challenged, generic companies can seek FDA approval to market their own versions of the drug. They must demonstrate bioequivalence to the innovator product.
- Reformulation Strategies: Other pharmaceutical companies may develop their own proprietary formulations of the same API to gain market share, improve patient compliance, or extend market exclusivity through new patents on these improved formulations. This could involve developing extended-release versions, different dosage forms, or formulations with fewer side effects.
- Biosimilar/Biologic Landscape: If the API is a biologic, the landscape shifts to biosimilar competition, which is more complex than generic competition for small molecules. However, US Patent 8,747,902 specifically relates to a pharmaceutical formulation, which can apply to both small molecules and biologics, though the claims' specificity usually points to one or the other.
The existence of US Patent 8,747,902 indicates that the formulation itself is considered innovative and potentially offers advantages over previous formulations of the API. Competitors must carefully navigate this patent landscape to avoid infringement. This often involves conducting thorough freedom-to-operate (FTO) analyses and potentially seeking licenses or challenging existing patents.
What are the Potential Infringement Risks for New Formulations?
Developing new pharmaceutical formulations containing the same API as covered by US Patent 8,747,902 carries significant infringement risks. Infringement occurs if a new formulation falls within the scope of any of the patent's asserted claims.
Key considerations for assessing infringement risk include:
- Claim Construction: The precise meaning of terms used in the patent claims is critical. This is often determined through a process called claim construction, which can be a subject of litigation.
- Direct Infringement: A new formulation directly infringes if it includes all the elements claimed in at least one independent claim. This requires a detailed comparison of the competitor's formulation composition and properties against the patent's claims.
- Indirect Infringement: This can occur through induced infringement (actively encouraging another party to infringe) or contributory infringement (selling a component that is a material part of the patented invention, knowing it will be used to infringe).
- Doctrine of Equivalents: Even if a new formulation does not precisely match the claim language, it can still infringe under the doctrine of equivalents if it performs substantially the same function in substantially the same way to achieve substantially the same result.
Companies developing new formulations must perform comprehensive freedom-to-operate (FTO) studies, which analyze all relevant patents to identify potential infringement risks. This typically involves consulting with patent attorneys and patent search specialists. Strategies to mitigate infringement risk include:
- Designing Around the Patent: Modifying the new formulation to avoid incorporating all the elements of a patent claim.
- Seeking a License: Negotiating with the patent holder for permission to use the patented technology.
- Challenging the Patent: Attempting to invalidate the patent through post-grant review proceedings at the USPTO or through litigation.
How Does This Patent Relate to Existing or Potential Generic Competition?
US Patent 8,747,902 plays a crucial role in the context of generic competition for any drug product utilizing the patented formulation.
- Blocking Generic Entry: This patent, if still in force and covering a key aspect of the marketed drug product, can prevent generic manufacturers from launching their products. Generic manufacturers typically must navigate a complex web of patents, including those covering the API itself, the formulation, the method of use, and manufacturing processes.
- Patent Litigation: The issuance of this patent often leads to litigation when a generic company files an Abbreviated New Drug Application (ANDA) and seeks to market a generic version. The patent holder (AstraZeneca AB) may sue the ANDA filer for infringement. This can trigger a 30-month stay of FDA approval for the generic drug, under the provisions of the Hatch-Waxman Act, during which patent validity and infringement are litigated.
- Key Evidence in ANDA Litigation: The claims and prosecution history of US Patent 8,747,902 would be central to any such litigation. Generic companies will argue that their product does not infringe the patent or that the patent is invalid.
- Formulation Differences as a Strategy: Generic companies might attempt to differentiate their product by developing a formulation that is not covered by this patent, while still being bioequivalent and therapeutically effective. This requires careful analysis of the patent's claims and the development of alternative formulations.
The existence of this patent signifies a proprietary formulation that offers potential advantages, thereby creating a barrier to entry for generic competitors until the patent expires or is overcome.
Key Takeaways
- US Patent 8,747,902, issued to AstraZeneca AB, protects a specific pharmaceutical formulation comprising an API, buffering agent, disaggregating agent, and binding agent.
- The patent's claims are focused on the composition and specific ratios of these components, aiming to enhance therapeutic properties.
- The patent term is 20 years from the filing date (June 11, 2008), potentially extended by PTA and PTE, indicating an expiration around June 11, 2028, or later.
- This patent acts as a barrier to generic competition by protecting the specific formulation, potentially leading to Hatch-Waxman Act litigation.
- Developing new formulations requires careful freedom-to-operate analysis to avoid infringing the claims of US Patent 8,747,902 and other relevant patents.
Frequently Asked Questions
What specific active pharmaceutical ingredient (API) is covered by US Patent 8,747,902?
The patent abstract and claims describe "an active pharmaceutical ingredient." While the patent does not explicitly name a single API, it is understood to cover a class of compounds or a specific API that, when formulated according to the patent's specifications, exhibits advantageous properties. A thorough review of the patent's detailed description and prosecution history is required to identify the precise API or class of APIs intended.
Can generic companies develop a formulation of the same API if it does not precisely match the claimed excipients?
Yes, if a generic company can develop a formulation of the same API that does not contain all the elements recited in any of the patent's independent claims, it may avoid direct infringement. However, they must also consider potential infringement under the doctrine of equivalents and any other related patents.
What is the significance of the date of filing (June 11, 2008) for this patent?
The filing date establishes the priority date for the invention. This date is critical for determining the patent's term and for assessing whether the invention was novel and non-obvious at the time of filing, in comparison to prior art that existed before this date.
Does this patent prevent the use of the API for any therapeutic purpose?
No, this patent protects a specific formulation of the API. It does not prevent others from making, using, or selling the API itself for other purposes or in different formulations, provided those formulations do not infringe this patent.
What is the typical process for challenging the validity of a patent like US Patent 8,747,902?
Patent validity can be challenged through various legal mechanisms, including inter partes review (IPR) or post-grant review (PGR) proceedings at the U.S. Patent and Trademark Office (USPTO), or through patent litigation in federal court, often initiated as a defense against an infringement lawsuit.
Citations
[1] AstraZeneca AB. (2014). United States Patent 8,747,902: Pharmaceutical formulations. U.S. Patent and Trademark Office.
